Individual generic drug information
Extracted information for Ranolazine only.
As adjunctive therapy in the treatment of stable angina in patients inadequately controlled or intolerant of first- line antianginal therapies ▶BY MOUTH ▶Adult: Initially 375 mg twice daily for 2–4 weeks, then increased to 500 mg twice daily, then adjusted according to response to 750 mg twice daily; reduced if not tolerated to 375–500 mg twice daily
Source page 246
Body-weight less than 60 kg. elderly. moderate to severe congestive heart failure. QT interval prolongation
Source page 246
Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (November 2012) that ranolazine (Ranexa ®) is not recommended for use within NHS Scotland.
Source page 246
Extracted information for Ranolazine only.
→Appendix 1: ranolazine
Source page 246
▶Common or very common Asthenia. constipation. headache. vomiting ▶Uncommon Anxiety. appetite decreased. confusion. cough. dehydration. dizziness postural. drowsiness. dry mouth. gastrointestinal discomfort. gastrointestinal disorders. haemorrhage. hallucination. hot flush. hypotension. insomnia. joint swelling. muscle cramps. muscle weakness. pain in extremity. peripheral oedema. QT interval prolongation. sensation abnormal. skin reactions. syncope. tinnitus. tremor. urinary disorders. urine discolouration. vertigo. vision disorders. weight decreased ▶Rare or very rare Acute kidney injury. altered smell sensation. angioedema. consciousness impaired. coordination abnormal. erectile dysfunction. gait abnormal. hearing impairment. hyponatraemia. memory loss. oral hypoaesthesia. pancreatitis. peripheral coldness
Source page 246
Manufacturer advises avoid unless essential—no information available.
Source page 246
Manufacturer advises avoid—no information available.
Source page 246
Manufacturer advises caution in mild impairment; avoid in moderate to severe impairment (risk of increased exposure). Dose adjustments Manufacturer advises careful dose titration in mild impairment.
Source page 246
Use with caution if eGFR 30–80 mL/minute/1.73 m2; avoid if eGFR less than 30 mL/minute/1.73 m2.
Source page 246
Extracted information for Ranolazine only.
There can be variation in the licensing of different medicines containing the same drug. Modified-release tablet CAUTIONARY AND ADVISORY LABELS 25 ▶Ranexa (A. Menarini Farmaceutica Internazionale SRL) Ranolazine 375 mg Ranexa 375mg modified-release tablets | 60 tablet P £48.98 DT = £48.98 Ranolazine 500 mg Ranexa 500mg modified-release tablets | 60 tablet P £48.98 DT = £48.98 Ranolazine 750 mg Ranexa 750mg modified-release tablets | 60 tablet P £48.98 DT = £48.98 SELECTIVE SINUS NODE IF INHIBITORS
Source pages 246, 247
Extracted information for Ranolazine only.
Patient alert card to be provided.
Source page 246
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
Initially 375 mg twice daily for 2–4 weeks, then
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 246
